REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts

Inclusion Criteria: * Age 18 or older * Anterior circulation intracanial large artery occlusion isolated (Intracranial ICA and/or MCA) proved on CTA or MRA. * Symptoms onset \< 24h at imaging * Indication for MT and fulfillment of the following brain imaging criteria : 1. Perfusion imaging: An initial infarct volume (ischemic core on DWI or CTP calculated by the RAPID software) of less than 70 ml, a ratio between the critically hypoperfused lesion volume (calculated by RAPID with a TMax\>6s) and initial infarct volume of 1.8 or more, and an absolute difference between those 2 volumes of 15 ml or more. OR (if perfusion imaging not available or uninterpretable) : 2. CORE CLINICAL MISMATCH: Core calculated on DWI by RAPID, \<25 mL if NIHSS 6-20 and \<50 mL if NIHSS\>20 OR (if RAPID results are not considered reliable by the clinician) : 3. CORE CLINICAL MISMATCH according to the clinician evaluation * Pre-stroke mRS ≤ 2 * NIHSS ≥ 6 Exclusion Criteria: * Contraindication to MT * Patient over 80 years old with \>10 microbleeds on pre-treatment MRI * Pre-existing dependency with mRS ≥3. * Known tandem ICA-MCA occlusions requiring stenting * ASPECT\<6 on NCCT or DWI-MRI * Known hypersensitivity to cangrelor or to any of the excipients (mannitol, sorbitol) * History of previous intracranial hemorrhage * Evidence of active bleeding or acute trauma (fracture) on examination * Recent surgery with a significant risk of bleeding * VKA oral anticoagulation with INR \>1.7 * Curative heparin or direct oral anticoagulants (DOACs) in previous 48 hours with specific DOAC dosage ≥50 ng/ml and abnormal thrombin time for patients on dabigatran or abnormal specific anti-Xa activity for patients on apixaban, edoxaban, or rivaroxaban * Platelet count \<100 000/ mm3 * Woman of childbearing age without a pregnancy test or with a positive serum pregnancy test * Patient benefiting from a legal protection * Non-membership of a national insurance scheme * Opposition of the patient or (in case of inclusion as a matter of urgency) of the trustworthy person * Participation in another study regarding AIS care interfering with this study.